Four in 10 Patients Receiving Chemo Develop Chronic Painful Neuropathy
By Elana Gotkine HealthDay Reporter
TUESDAY, Feb. 4, 2025 -- The pooled prevalence of chronic painful neuropathy is 41.22 percent among individuals with chemotherapy-induced peripheral neuropathy (CIPN), according to a meta-analysis published online Jan. 28 in Regional Anesthesia & Pain Medicine.
Ryan S. D'Souza, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a systematic review and meta-analysis to examine the prevalence of chronic painful neuropathy among patients diagnosed with CIPN. Estimates from each study were transformed using double arcsine transformation and pooled in a meta-analysis. Data were included from 77 studies from 28 countries, encompassing 10,962 patients with CIPN.
The researchers found that the pooled prevalence of those reporting chronic painful neuropathy among those diagnosed with CIPN was estimated at 41.22 percent. Across studies, there was considerable heterogeneity (I2 = 95.27 percent). Patients treated with platinum-based agents and taxanes had the highest prevalence of chronic painful CIPN (40.44 and 38.35 percent, respectively); among primary cancers, the highest prevalence was reported by those with lung cancer (60.26 percent). Nonsignificant moderators of prevalence estimates included study design, human development index, and publication year.
"The wide variability in prevalence rates across different countries, continents, chemotherapy regimens, and primary cancer history underscores the need for tailored strategies to address this debilitating condition," the authors write.
One author disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Screening Colonoscopy IDs Similar Rates of CRC for 45 to 49 as 50 to 54 Years
TUESDAY, June 10, 2025 -- Rates of colorectal cancer detection through colonoscopy screening are similar for adults aged 45 to 49 years and 50 to 54 years, according to a research...
Systemic Social Factors May Increase the Risk of Psychotic Experiences
TUESDAY, June 10, 2025 -- Experiences with discrimination may increase the risk of psychotic experiences among marginalized young adults, according to a study published online May...
New Classification System Accurate for Nasal Deformities in Cleft Lip and Palate
TUESDAY, June 10, 2025 -- A new classification system seems to be highly accurate for evaluating nasal deformities in infants with cleft lip and palate (CLP), according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.